Full-Time

Organ Health Specialist

Abdominal Transplant

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Biotechnology
Healthcare

Compensation Overview

$180k - $200kAnnually

+ Base Salary + Commissions + Car Allowance + Restricted Stock Units (RSUs)

Senior, Expert

Company Historically Provides H1B Sponsorship

Pittsburgh, PA, USA

Remote role with field-based responsibilities requiring 3-4 days of travel per week.

Category
Customer Success Management
Sales & Account Management
Required Skills
Sales

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree or equivalent experience required.
  • Minimum of 6 years of progressive sales experience, ideally in lab-developed tests, diagnostics, or transplant-related specialties.
  • Deep understanding of transplant settings or similar specialty medicine.
  • Proven track record of closing deals, driving growth, and building strong client relationships.
  • Experience launching new products and building a brand in the transplant market.
  • Strong problem-solving abilities with a creative, independent approach to overcoming challenges.
  • Excellent communication, presentation, and interpersonal skills.
Responsibilities
  • Drive sales and adoption of Prospera, a non-invasive blood test for transplant patients.
  • Promote Renasight, a genetic test that identifies potential genetic causes of kidney disease.
  • Achieve and exceed sales goals through strategic sales initiatives, relationship-building, and effective territory management.
  • Drive market adoption of transplant-focused genetic testing solutions by educating and engaging key stakeholders.
  • Leverage industry expertise to establish credibility and effectively position genetic testing solutions within the transplant ecosystem.
  • Develop and execute tailored business plans that align with sales objectives, optimize resources, and address unique market dynamics.
  • Cultivate and maintain relationships with key opinion leaders (KOLs) in transplant and related specialties.
  • Navigate complex sales environments with a proactive, problem-solving mindset.
  • Represent the company with professionalism and technical expertise, staying up to date on advancements in genetic testing, laboratory diagnostics, and the transplant landscape.
  • Work independently while collaborating cross-functionally to drive business growth.
Desired Qualifications
  • Existing relationships with KOLs in transplant or similar fields preferred.

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and organ health assessment. Their products include the Signatera test for cancer patients and the Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing specialized testing services directly to healthcare providers and patients, ensuring early detection of health issues. The company's goal is to improve patient care through advanced genetic testing solutions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • Growing personalized medicine trend enhances need for Natera's customized genetic tests.
  • Expansion of telehealth services aligns with Natera's remote genetic counseling offerings.

What critics are saying

  • Allegations of deceptive practices could harm Natera's reputation and lead to legal issues.
  • New Prospera Heart features may face adoption challenges without independent validation.
  • Ongoing legal investigations could result in financial penalties affecting Natera's stability.

What makes Natera unique

  • Natera's Signatera test offers significant lead time in detecting cancer recurrence.
  • Prospera Heart test integrates Donor Quantity Score for enhanced transplant rejection detection.
  • Panorama NIPT uniquely determines fetal RhD status, aiding in prenatal care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection